



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/121,368	07/23/98	LINDEN	B S13.12-0036

JOSEPH R KELLY
WESTMAN CHAMPLIN & KELLY
900 SECOND AVENUE SOUTH
SUITE 1600 INTERNATIONAL CENTRE
MINNEAPOLIS MN 55402-3319

QM12/0118

EXAMINER

MCDERMOTT, C

ART UNIT

PAPER NUMBER

3763

DATE MAILED:

01/18/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Interview Summary

Application No.
09/121,368

Applicant
Lindin et al.

Examiner
Corrine M. McDermott

Group Art Unit
3763



All participants (applicant, applicant's representative, PTO personnel):

(1) Corrine M. McDermott

(3) _____

(2) Joseph Kelly

(4) _____

Date of Interview Jan 14, 2000

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No. If yes, brief description:

Agreement ☒ was reached. ☐ was not reached.

Claim(s) discussed: Claims of proposed amendment.

Identification of prior art discussed:

Art of record.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Discussed proposed amendment which amended independent claims in an effort to overcome rejection of claims as anticipated by Lemelson. Examiner agrees that amendments overcome art rejection. Discussed method claims, amendments to which were not presented. Counsel stated that some would be canceled and that those requiring the administration of genetic material would remain, unamended, with supporting arguments to their allowability.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

CORRINE M. MCDERMOTT
PRIMARY EXAMINER
ART UNIT 3763

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.

WESTMAN, CHAMPLIN & KELLY

A PROFESSIONAL ASSOCIATION

NICKOLAS E. WESTMAN
JUDSON K. CHAMPLIN
JOSEPH R. KELLY
STEVEN M. KOEHLER
DAVID D. BRUSH
JOHN D. VELDHUIS-KROEZE
DEIRDRE MEGLEY KYALE
THEODORE M. MACER
PETER S. DAKDI, Ph.D.
CHRISTOPHER R. CHRISTENSON
JOHN A. WIERG
BRIAN D. KAUL

SUITE 1600 - INTERNATIONAL CENTRE
900 SECOND AVENUE SOUTH
MINNEAPOLIS, MINNESOTA 55402-3319

PATENT, TRADEMARK, COPYRIGHT
LAW AND RELATED ISSUES
(612) 334-3222 TELEPHONE
(612) 334-3312 FACSIMILE

FAX Transmission Sheet

VISALA CHEPURI GOSWITZ, Ph.D.
PATENT AGENT

Date : January 14, 2000

To : C. McDermott

Company : Patent Office

Fax No.: 703-306-4520

From : Joseph R. Kelly

You should receive 8 page(s) including this cover sheet.

NOTE: The information contained in this facsimile message may be privileged or confidential. It is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivery to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is neither intended nor permissible. If you have received this communication in error, please immediately notify us by telephone at the above number (call collect), and return the original to us at the above address via U.S. Postal Service.

*Purpose
only genetic
Material in
method claims
- need to search to
find that
argument is that in
Genetic material
don't use genetic
Material*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bradley C. Linden et al.
Serial No.: 09/121,368
Filed : July 23, 1998
For : INTRA-EXTRAVASCULAR DRUG
DELIVERY CATHETER AND METHOD
Docket No.: S13.12-0036

Group Art Unit: 3763
Examiner:
C. McDermott

PROPOSED AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

I HEREBY CERTIFY THAT THIS
PAPER IS BEING SENT BY U.S.
MAIL, FIRST CLASS, TO THE
ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, D.C.
20231, THIS

____ DAY OF _____,
19____.

PATENT ATTORNEY

Sir:

This is in response to the Office Action mailed on November 5, 1999. Please amend the above-identified application as follows:

IN THE CLAIMS

Please cancel claims 130, 131, 140, 146, 151-163 and 165 and amend claims 57, 86, 91, 103, 120 and 132 as follows:

57. (Amended) An intravascular therapeutic catheter comprising:
an elongate catheter body having a distal portion;
a tissue penetrating member having a tissue penetrating tip, disposed at an angle relative to the catheter body, the angle opening in a proximal direction of no more than approximately 90 degrees, the tissue penetrating member being disposed proximate the distal portion, operably coupled to the elongate catheter body, and having a first non-penetrating position and a second tissue penetrating position;
and

-2-

an actuator member disposed proximate the distal portion and operably coupled to the tissue penetrating member, for moving the tissue penetrating member from one of the first or second positions [in a direction substantially non-parallel to the catheter body] to the other of the first or second positions, the actuator adding energy to the tissue penetrating member as the tissue penetrating member moves from the first position to the second position.

86. (Amended) An intravascular therapeutic catheter comprising:
an elongate catheter body having a distal portion and an axis;
a tissue penetrating member having a tissue penetrating tip disposed at an angle relative to the axis, the angle opening in a proximal direction and being of no more than approximately 90 degrees, the tissue penetrating member being disposed proximate the distal portion and operably coupled to the elongate catheter body and having a first non-penetrating position and a second tissue penetrating position;
and
an actuator member disposed proximate the distal portion and operably coupled to the tissue penetrating member, for moving the tissue penetrating member from one of the first or second positions to the other of the first or second positions in a substantially transverse path with respect to the axis.

91. (Amended) An intravascular therapeutic catheter comprising:
an elongate catheter body having a distal portion and an axis;
a tissue penetrating member having a tissue penetrating tip disposed at an angle relative to the axis, the

-3-

angle opening in a proximal direction and being of no more than approximately 90 degrees, the tissue penetrating member being disposed proximate the distal portion and operably coupled to the elongate catheter body and having a first non-penetrating position and a second tissue penetrating position; and

an actuator member disposed proximate the distal portion and operably coupled to the tissue penetrating member, for moving the tissue penetrating member a limited distance from one of the first or second positions in a direction substantially non-parallel to the catheter body to the other of the first or second positions.

103. (Amended) A method for treating cardiac tissue comprising the steps of:

providing an intravascular therapeutic catheter having an elongate catheter body, an actuator and a tissue penetrating member having a tissue penetrating tip disposed at an angle relative to the axis, the angle opening in a proximal direction and being of no more than approximately 90 degrees, the tissue penetrating member being operably coupled to the catheter body and disposed proximate a distal portion of the catheter body, the tissue penetrating member having a first non-penetrating position and a second tissue penetrating position;

navigating the catheter through vasculature to a treatment site proximate the cardiac tissue; and

adding energy to the tissue penetrating member to move the tissue penetrating member from the first position in a direction substantially non-parallel to the catheter body to the second position.

-4-

120. (Amended) A method for treating cardiac tissue comprising the steps of:

providing an intravascular therapeutic catheter having an elongate catheter body, an actuator and a tissue penetrating member having a tissue penetrating tip disposed at an angle relative to the axis, the angle opening in a proximal direction and being of no more than approximately 90 degrees, the tissue penetrating member being operably coupled to the catheter body and disposed proximate a distal portion of the catheter body, the tissue penetrating member having a first non-penetrating position and a second tissue penetrating position;

navigating the catheter through vasculature to a treatment site proximate the cardiac tissue; and

moving the tissue penetrating member from one of the first or second positions to the other of the first or second positions in a substantially transverse path with respect to a longitudinal axis of the catheter body.

132. (Amended) A method for treating cardiac tissue comprising the steps of:

providing an intravascular catheter of the type having an elongate catheter body and a tissue penetrating member operably coupled to the catheter body and disposed proximate a distal portion of the catheter body, the penetrating member having a first non-penetrating position and a second tissue penetrating position;

navigating the catheter through vasculature to a treatment site proximate the cardiac tissue to be treated;

moving the tissue penetrating member from one of the first or second positions in a direction substantially non-

-5-

parallel to the catheter body to the other of the first or second positions; and delivering a drug comprising a genetic material to the treatment site.

REMARKS

The Commissioner is authorized to charge any fee deficiency required by this paper or credit any overpayment to Deposit Account No. 23-1123.

Respectfully submitted,

WESTMAN, CHAMPLIN & KELLY, P.A.

By: _____

Joseph R. Kelly, Reg. No. 34,847
Suite 1600 - International Centre
900 Second Avenue South
Minneapolis, Minnesota 55402-3319
Phone: (612) 334-3222 Fax: (612) 334-3312

JRK:smn